‘Atypical’ antipsychotics: where does ziprasidone fit?

References

• Seeman P Dopamine receptor sequences. Therapeutic levels of neuroleptics occupy D2 receptors, clozapine occupies D4. Neuropsychopharmacology7, 261–284 (1992).
   PubMedGoogle Scholar
• Farde L, Nordstrom AL, Wiesel FA et al. Positron emission tomographic analysis of central D1 and D2 dopamine receptor occupancy in patients treated with classical neuroleptics and clozapine. Relation to extrapyramidal side effects. Arch. Gen. PTchiatry 49, 538–544 (1992).
   Google Scholar
• Kane J, Honigfeld G, Singer J et al Clozapine for the treatment-resistant schizophrenic. A double-blind comparison with chlorpromazine. Arrh. Gen Psychiatry 45, 789–796 (1998).
   Google Scholar
• Pickar D, Owen RR, Litman RE et al. Clinical and biologic response to clozapine in patients with schizophrenia. Crossover comparison with fluphenazine. Arch. Gen. PTchiatry49, 345–353 (1992).
   PubMed Web of Science ®Google Scholar
• Meltzer HY, Matsubara S, Lee JC. Classification of typical and atypical antipsychotic drugs on the basis of dopamine D-1, D-2 and serotonin2 pKi values. J. Pharmacol Exp. Ther. 251, 238–246 (1989).
   Google Scholar
• Meltzer HY, Matsubara S, Lee JC. The ratios of serotonin2 and dopamine2 affinities differentiate atypical and typical antipsychotic drugs. PFchopharmacol Bull. 25, 390–392 (1989).
   Google Scholar
• Kerwin RVV. The new atypical antipsychotics. A lack of extrapyramidal side effects and new routes in schizophrenia research. Br. fiychiatry164, 141–148 (1994).
   Google Scholar
• Fleischhacker WW Hummer M. Drug treatment of schizophrenia in the 1990s. Achievements and future possibilities in optimising outcomes. Drugs 53, 915-929 (1997).
   Google Scholar
• Geddes J, Freemantle N, Harrison P et al. Atypical antipsychotics in the treatment of schizophrenia: systematic overview and meta-regression analysis. BE Med. 1. 321, 1371–1376 (2000).
   Google Scholar
• Leucht S, Pitschel-Walz G, Abraham D et al. Efficacy and extrapyramidal side effects of the new antipsychotics olanzapine, quetiapine, risperidone and sertindole compared to conventional antipsychotics and placebo. A meta-analysis of randomized controlled trials. Schizoph. Res. 35, 51–68 (1999).
   Google Scholar
• Arvanitis LA, Miller BG. Multiple fixed doses of `Seroquel' (Quetiapine) in patients with acute exacerbation of schizophrenia: a comparison with haloperidol and placebo. Biol. Bychiatry 42, 233–246 (1997).
   PubMed Web of Science ®Google Scholar
• Kapur S, Zipursky RB, Remington G. Clinical and theoretical implications of 5-HT2 and D2 receptor occupancy of clozapine, risperidone and olanzapine in schizophrenia. Am J. PFchiatry156, 286–293 (1999).
   Google Scholar
• Kapur S, Zipursky RB, Remington G et al 5-HT2 and D2 receptor occupancy of olanzapine in schizophrenia: a PET investigation. Am. J. PFchiatry155, 921–928 (1998).
   Google Scholar
• Kapur S, Remington G, Zipursky RB et al The D2 dopamine receptor occupancy of risperidone and its relationship to extrapyramidal symptoms: a PET study. life Sci. 57, 103–107 (1995).
   PubMed Web of Science ®Google Scholar
• Kapur S, Remington G. Atypical antipsychotics: new directions and new challenges in the treatment of schizophrenia. In: Annual Review in Medicine: Selected Topics in the Clinical Sciences. Caskey C (Ed.), Annual Reviews, Palo Alto, USA. 503–517 (2001).
   Google Scholar
• Remington G, Kapur S, Zipursky R. Antipsychotic drug side effects. In: Schizophrenia: A New Guide for Clinicians. Csemansky J (Ed.), Marcel Dekker, New York, USA. In press.
   Google Scholar
• Mir S, Taylor D. Atypical antipsychotics and hyperglycaemia. Int. Clin. Psychopharmacol 16, 63–73 (2001).
   PubMed Web of Science ®Google Scholar
• Remington G, Kapur S. Atypical antipsychotics: are some more atypical than others? Bychopharmacology (erl) 148, 3–15 (2000).
   PubMed Web of Science ®Google Scholar
• Meltzer HY. Outcome in schizophrenia: beyond symptom reduction. J. Clin. Psychiatry60 (Suppl. 3), 3–7 (1999).
   Google Scholar
• Corbett RGL, Shipley JE, Shukla U et al lloperidone: preclinical profile and early clinical evaluation. CNS Drug -Rev 3, 120–147 (1997).
   Google Scholar
• Carson WH, Ali M, Dunbar G et al A double-blind, placebo-controlled trial of aripiprazole and haloperidol. Schizophr Res. 49, 221–222 (2001).
   Google Scholar
• Weinberger DR. The biological basis of schizophrenia: new directions. j Clin. Psychiatry 58 (Suppl. 10), 22–27 (1997).
   Google Scholar
• Kapur S, Remington G. Dopamine D2 receptors and their role in atypical antipsychotic action: still necessary and may even be sufficient. Biol. liychiatr In press.
   Google Scholar
• Kinon BJ, Lieberman JA. Mechanisms of action of atypical antipsychotic drugs: a critical analysis. Rychopharmacology (Berl.) 124, 2–34 (1996).
   PubMed Web of Science ®Google Scholar
• Seeger TF, Seymour PA, Schmidt AW et al Ziprasidone (CP-88,059): a new antipsychotic with combined dopamine and serotonin receptor antagonist activity. Pharmacol Exp. Ther. 275, 101–113 (1995).
   Google Scholar
• Waddington JL, Scully PJ, O'Callaghan E. The new antipsychotics and their potential for early intervention in schizophrenia. Schizophr. Res. 28, 207–222 (1997).
   PubMedGoogle Scholar
• Nordstrom AL, Farde L, Wiesel FA et al Central D2-dopamine receptor occupancy in relation to antipsychotic drug effects: a double-blind PET study of schizophrenic patients. Biol. Psychiatry 33, 227–235 (1993).
   Google Scholar
• Kapur S, Zipursky R, Jones C et al Relationship between dopamine D2 occupancy, clinical response and side effects: a double-blind PET study of first-episode schizophrenia. Am. J. Psychiatry 157, 514–520 (2000).
   Google Scholar
• Bench CJ, Lammertsma AA, Grasby PM et al The time course of binding to striatal dopamine D2 receptors by the neuroleptic ziprasidone (CP-88,059-01) determined by positron emission tomography. PFchopharmacology (Berl.) 124, 141–147 (1996).
   Google Scholar
• Miceli JJ, Gunn IQ, Rubin RII. 5-HT2 and D2 receptor occupancy of ziprasidoen in healthy volunteers. 35th Annual Meeting of the American College of Neuropsychopharmacology. San Juan, Puerto Rico (1996).
   Google Scholar
• Fischman AJ, Bonab AA, Babich JW et al Positron emission tomographic analysis of central 5-hydroxytryptamine2 receptor occupancy in healthy volunteers treated with the novel antipsychotic agent, ziprasidone. j Pharmacol Exp. Ther. 279, 939–947 (1996).
   Google Scholar
• Seeman P, Tallerico T Antipsychotic drugs which elicit little or no parkinsonism bind more loosely than dopamine to brain D2 receptors, yet occupy high levels of these receptors. Mal fisychtry3, 123–134 (1998).
   Google Scholar
• Seeman P, Tallerico T Rapid release of antipsychotic drugs from dopamine D2 receptors: an explanation for low receptor occupancy and early clinical relapse upon withdrawal of clozapine or quetiapine. Am. PTchtry156, 876–884 (1999).
   Google Scholar
• Kapur S, Seeman P. Does fast dissociation from the dopamine D2 receptor explain the action of atypical antipsychotics? A new hypothesis. Ainj Bychiatry158, 360–369 (2001).
   PubMed Web of Science ®Google Scholar
• Miceli JJ, Wilner KD, Hansen RA et al. Single- and multiple-dose pharmacokinetics of ziprasidone under non-fasting conditions in healthy male volunteers. BE j Clin. Pharmacol 49, 5S-13S (2000).
   Google Scholar
• Aweeka F, Jayesekara D, Horton M et al The pharmacokinetics of ziprasidone in subjects with normal and impaired renal function. BE j Clin. Pharmacol 49, 27S-33S (2000).
   Google Scholar
• Everson G, Lasseter KC, Anderson KE et al. The pharmacokinetics of ziprasidone in subjects with normal and impaired hepatic function. Br. Clin. Pharmacol 49, 21S-26S (2000).
   Google Scholar
• Wilner KD, Tensfeldt TG, Bans B et al. Single- and multiple-dose pharmacokinetics of ziprasidone in healthy young and elderly volunteers. BE j Clin. Pharmacol 49, 15S-20S (2000).
   Google Scholar
• Miceli JJ, Wilner K, Tensfeldt TG. Pharmacokinetics of im. ziprasidone in health volunteers: results from two controlled studies. 39th Annual Meeting of the American College of Neuropsychopharmacology. San Juan, Puerto Rico (2000).
   Google Scholar
• Prakash C, Kamel A, Gummerus J et al Metabolism and excretion of a new antipsychotic drug, ziprasidone, in humans. Drug Metab. Dispos. 25, 863–872 (1997).
   PubMed Web of Science ®Google Scholar
• Miceli J, Hunt T, Cole MJ et al The pharmacokinetics of CP-88,059 in healthy male volunteers following oral and iv. administration. Clin. Pharmacol Ther. 55, 142 (1994).
   Google Scholar
• Prakash C, Kamel A, Anderson W et al. Metabolism and excretion of the novel antipsychotic drug ziprasidone in rats after oral administration of a mixture of 14C-and 3H-labeled ziprasidone. Drug- Metab. Dispos. 25, 206–218 (1997).
   Google Scholar
• Tandon R. Introduction. Ziprasidone appears to offer important therapeutic and tolerability advantages over conventional and some novel, antipsychotics. BE j Clin. Pharmacol 49, 1S-3S (2000).
   Google Scholar
• Prakash C, Kamel A, Cui D et al Identification of the major human liver cytochrome P450 isoform(s) responsible for the formation of the primary metabolites of ziprasidone and prediction of possible drug interactions. BE J. Clin. Phalmacol 49, 35S-42S (2000).
   Google Scholar
• Miceli JJ, Anziano RJ, Robarge L et al The effect of carbamazepine on the steady-state pharmacokinetics of ziprasidone in healthy volunteers. BE J. Gun. Pharmacol 49, 65S-70S (2000).
   Google Scholar
• Miceli JJ, Smith M, Robarge L et al The effects of ketoconazole on ziprasidone pharmacokinetics-a placebo-controlled crossover study in healthy volunteers. BE j Clin. Phalmacol 49, 71S-76S (2000).
   Google Scholar
• Muirhead GJ, Harness J, Holt PR et al. Ziprasidone and the pharmacokinetics of a combined oral contraceptive. BE j Clin. Pharmacol 49, 49S-56S (2000).
   Google Scholar
• Wilner KD, Demattos SB, Anziano RJ et al. Ziprasidone and the activity of cytochrome P450 2D6 in healthy extensive metabolizers. BE J. Gun. Pharmacol 49, 43S-47S (2000).
   Google Scholar
• Wilner KD, Hansen RA, Folger CJ et al. The pharmacokinetics of ziprasidone in healthy volunteers treated with cimetidine or antacid. BE J. Gun. Pharmacol 49, 57S-60S (2000).
   Google Scholar
• Apseloff G, Mullet D, Wilner KD et al. The effects of ziprasidone on steady-state lithium levels and renal clearance of lithium. Br. Clin. Pharmacol 49, 61S-64S (2000).
   Google Scholar
• Keck P, Buffenstein A, Ferguson J et al. Ziprasidone 40 and 120 mg/day in the acute exacerbation of schizophrenia and schizoaffective disorder: a 4-week placebo-controlled trial. Bychopharmacology (Bert.) 140, 173–184 (1998).
   Google Scholar
• •• Double-blind, placebo-controlled trial.
   Google Scholar
• Daniel DG, Zimbroff DL, Potkin SG et al. Ziprasidone 80 mg/day and 160 mg/day in the acute exacerbation of schizophrenia and schizoaffective disorder: a 6-week placebo-controlled trial. Ziprasidone Study Group. Neumpsychopharmacology20, 491–505 (1999).
   Google Scholar
• ••Double-blind, placebo-controlled trial.
   Google Scholar
• Keck PE, Jr., Reeves KR, Harrigan ER Ziprasidone in the short-term treatment of patients with schizoaffective disorder: results from two double- blind, placebo-controlled, multicenter studies. J. Clin. Psychopharmacol 21, 27–35 (2001).
   PubMed Web of Science ®Google Scholar
• Goff DC, Posever T, Herz L et a/. An exploratory haloperidol-controlled dose-finding study of ziprasidone in hospitalized patients with schizophrenia or schizoaffective disorder. J. Clin. Psychophannacol 18, 296–304 (1998).
   Google Scholar
• ••Double-blind trial with haloperidol asactive comparator.
   Google Scholar
• Brook S, Lucey JV, Gunn KP. Intramuscular ziprasidone compared with im. haloperidol in the treatment of acute psychosis. Ziprasidone I.M. Study Group. J. Clin. Psychiatry 61, 933–941, 2000.
   Google Scholar
• Lesem MD, Zajecka JM, Swift RII et al Intramuscular ziprasidone, 2 mg versus 10 mg, in the short-term management of agitated psychotic patients. j Clin. Psychiatry62, 12–18 (2001).
   Google Scholar
• ••Double-blind trial involving differentdoses of im. ziprasidone.
   Google Scholar
• Arato M, O'Connor R, Bradbury JE et al Ziprasidone in the long-term treatment of negative symptoms and prevention of schizophrenia. XXth Collegium Internationale Neuro-Psychopharmacologicum (CINP). Melbourne, Australia (1996).
   Google Scholar
• Kingsbury SJ, Fayek M, Trufasiu D et al The apparent effects of ziprasidone on plasma lipids and glucose. J. Clin. Psychiatry 62, 347–349 (2001).
   PubMed Web of Science ®Google Scholar
• Keck PE, Jr., McElroy SL, Arnold LM. Ziprasidone: a new atypical antipsychotic. Expert Opin. Pharmacother. 2, 1033–1042 (2001).
   PubMedGoogle Scholar
• •Review article.
   Google Scholar
• Allison DB, Casey DE. Antipsychotic- induced weight gain: a review of the literature.j Clin. PFhiatry 62, 22–31 (2001).
   PubMed Web of Science ®Google Scholar
• Hagg S, Joelsson L, Mjorndal T et al. Prevalence of diabetes and impaired glucose tolerance in patients treated with clozapine compared with patients treated with conventional depot neuroleptic medications. j Clin. PFhiatry59, 294–299 (1998).
   PubMed Web of Science ®Google Scholar
• Wirshing DA, Spellberg BJ, Erhart SM etal. Novel antipsychotics and new onset diabetes. Biol. Psychiatry 44, 778–783 (1998).
   Google Scholar
• Waddington JL, O'Callaghan E. What makes an antipsychotic 'atypical'? CNS Drugs7, 341–346 (1997).
   Google Scholar
• Wyatt RJ, Green MF, Tuma AH. Long-term morbidity associated with delayed treatment of first admission schizophrenic patients: a re-analysis of the Camarillo State Hospital data Bychol Med. 127, 261–268 (1997).
   Google Scholar
• McGorry PD. The influence of illness duration on syndrome clarity and stability in functional psychosis: does the diagnosis emerge and stabilise with time? Aust. NZI. Psychiatry28, 607–619 (1994).
   PubMed Web of Science ®Google Scholar
• Lieberman JA, Koreen AR, Chakos M et al Factors influencing treatment response and outcome of first-episode schizophrenia: implications for understanding the pathophysiology of schizophrenia. J. Gun. Psychiatry 57,5–9 (1996).
   Google Scholar
• American Psychiatric Association. Practice guideline for the treatment of patients with schizophrenia. Am. j Psychiaby 154,1-63 (1997). Affiliations
   Google Scholar